<DOC>
	<DOCNO>NCT00481455</DOCNO>
	<brief_summary>The purpose study evaluate anti-tumor activity safety Panzem NCD give combination daily oral fixed-dose temozolomide patient recurrent glioblastoma multiforme .</brief_summary>
	<brief_title>Phase 2 Study Panzem Nanocrystal Colloidal Dispersion ( NCD ) Combination With Fixed-Dose Temozolomide Patients With Recurrent Glioblastoma Multiforme ( GBM )</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>2-methoxyestradiol</mesh_term>
	<criteria>1 . A histologically confirm diagnosis recurrent/progressive primary WHO grade IV malignant glioma ( glioblastoma multiforme gliosarcoma ) . Patients recurrent disease whose diagnostic pathology confirm WHO grade IV malignant glioma ( glioblastoma multiforme gliosarcoma ) need rebiopsy . Patients prior lowgrade glioma eligible histologic assessment demonstrate transformation WHO grade IV malignant glioma . Pathology must confirm Duke University Medical Center 2 . Male female , age great equal 18 year . 3 . An interval least 2 week prior surgical resection ( conduct ) major surgery 4 week prior radiotherapy chemotherapy ( except nitrosoureas require 6 week ) enrollment protocol unless unequivocal evidence tumor progression patient recover toxicity associate therapy . However , patient treat chemotherapeutic agent VP16 would normally retreat short interval ( e.g . 21 day , 7 day schedule ) may treat usual starting time even less 4 week last prior dose chemotherapy . 4 . Karnofsky performance score great equal 70 % . 5 . Hematocrit &gt; 29 % , absolute neutrophil count &gt; 1,500 cells/*L , platelet &gt; 100,000 cells/*L. 6 . Serum creatinine &lt; 1.5 X upper limit normal ( ULN ) , serum glutamic oxaloacetic transaminase &lt; 2.5 X ULN ; bilirubin &lt; 1.5 time ULN . 7 . Signed informed consent form authorization use disclosure protect health information approve Institutional Review Board ( IRB ) prior patient entry . 8 . If sexually active , patient must use contraceptive measure duration treatment 4 week follow end study medication . 1 . Current , active systemic bleeding excessive risk bleeding define follow : stroke within previous 6 month , history central nervous system intraocular bleed , history septic endocarditis evidence intratumor hemorrhage pretreatment diagnostic imaging , except stable post operative grade 1 hemorrhage . 2 . Female patient pregnant breastfeed adult reproductive potential employ effective method birth control . ( Women childbearing potential must negative pregnancy test within 48 hour prior administration study medication ) . 3 . Concurrent severe and/or uncontrolled medical disease ( i.e . uncontrolled diabetes , congestive cardiac failure , myocardial infarction within 6 month , poorly control hypertension , history labile hypertension , history poor compliance antihypertensive regimen , chronic renal disease , active uncontrolled infection ) could compromise participation study . 4 . Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption study medication ( i.e . ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome , bowel obstruction , inability swallow liquid ) . 5 . Requirement therapy coumadin ( warfarin sodium ) . 6 . Patient &lt; 1 year free another primary malignancy except primary malignancy currently clinically significant require active intervention , primary malignancy basal cell skin cancer cervical carcinoma situ . Existence malignant disease allow . 7 . Patients unwilling unable comply protocol . 8 . Grade 2 great peripheral sensory neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Glioblastoma Multiforme</keyword>
	<keyword>temozolomide</keyword>
</DOC>